Abstract
AbstractSegmental instillation of lipopolysaccharide (LPS) by bronchoscopy safely induces transient airway inflammation in human lungs. This model enables investigation of pulmonary inflammatory mechanisms as well as pharmacodynamic analysis of investigational drugs. The aim of this work was to describe the transcriptomic profile of human segmental LPS challenge with contextualization to major respiratory diseases. Pre-challenge bronchoalveolar lavage (BAL) fluid and biopsies were sampled from 28 smoking, healthy participants, followed by segmental instillation of LPS and saline as control. Twenty-four hours post instillation, BAL and biopsies were collected from challenged lung segments. Total RNA of cells from BAL and biopsy samples were sequenced and analysed for differentially expressed genes (DEGs). After challenge with LPS compared with saline, 6316 DEGs were upregulated and 241 were downregulated in BAL, but only one DEG was downregulated in biopsy samples. Upregulated DEGs in BAL were related to molecular functions such as “Inflammatory response” or “chemokine receptor activity”, and upregulated pro-inflammatory pathways such as “Wnt-"/“Ras-"/“JAK-STAT” “-signaling pathway”. Furthermore, the segmental LPS challenge model resembled aspects of the five most prevalent respiratory diseases chronic obstructive pulmonary disease (COPD), asthma, pneumonia, tuberculosis and lung cancer and featured similarities with acute exacerbations in COPD (AECOPD) and community-acquired pneumonia. Overall, our study provides extensive information about the transcriptomic profile from BAL cells and mucosal biopsies following LPS challenge in healthy smokers. It expands the knowledge about the LPS challenge model providing potential overlap with respiratory diseases in general and infection-triggered respiratory insults such as AECOPD in particular.
Funder
Boehringer Ingelheim Pharma GmbH & Co. KG
Fraunhofer-Institut für Toxikologie und Experimentelle Medizin ITEM
Publisher
Springer Science and Business Media LLC
Reference82 articles.
1. Finney, L. J. et al. Validity of the diagnosis of pneumonia in hospitalised patients with COPD. ERJ Open Res 5, 00031-2019. https://doi.org/10.1183/23120541.00031-2019 (2019).
2. van der Poll, T. & Opal, S. M. Pathogenesis, treatment, and prevention of pneumococcal pneumonia. Lancet 374, 1543–1556. https://doi.org/10.1016/S0140-6736(09)61114-4 (2009).
3. Cillóniz, C., Civljak, R., Nicolini, A. & Torres, A. Polymicrobial community-acquired pneumonia: An emerging entity. Respirology 21, 65–75. https://doi.org/10.1111/resp.12663 (2016).
4. Farida, H. et al. Viruses and Gram-negative bacilli dominate the etiology of community-acquired pneumonia in Indonesia, a cohort study. Int. J. Infect. Dis. 38, 101–107. https://doi.org/10.1016/j.ijid.2015.07.023 (2015).
5. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease (2022 Report). https://goldcopd.org/2022-gold-reports/. Accessed 4 February 2022.